300 related articles for article (PubMed ID: 29301749)
21. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
22. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
Bastos DA; Antonarakis ES
Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
[TBL] [Abstract][Full Text] [Related]
24. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
25. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
Schlack K; Seitzer K; Wüstmann N; Humberg V; Grundmann N; Steinestel J; Tiedje D; Rahbar K; Krabbe LM; Bögemann M; Schrader AJ; Bernemann C
Sci Rep; 2022 Jul; 12(1):11846. PubMed ID: 35831403
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.
Ashizawa T; Nagata M; Nakamura S; Hirano H; Nagaya N; Lu Y; Horie S
Sci Rep; 2022 Oct; 12(1):18016. PubMed ID: 36289357
[TBL] [Abstract][Full Text] [Related]
27. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract][Full Text] [Related]
28. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
30. Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells.
Khan T; Lock JG; Ma Y; Harman DG; de Souza P; Chua W; Balakrishnar B; Scott KF; Becker TM
Sci Rep; 2022 Sep; 12(1):16159. PubMed ID: 36171234
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
32. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer.
Zavridou M; Smilkou S; Tserpeli V; Sfika A; Bournakis E; Strati A; Lianidou E
Clin Chem; 2022 Oct; 68(10):1323-1335. PubMed ID: 36093578
[TBL] [Abstract][Full Text] [Related]
33. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V
Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281
[TBL] [Abstract][Full Text] [Related]
34. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
35. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
[TBL] [Abstract][Full Text] [Related]
36. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT; Mostert B; Belderbos BPS; Buck SAJ; Helmijr JCA; Kraan J; Beaufort CM; Van MN; Oomen-de Hoop E; Sieuwerts AM; van IJcken WFJ; van den Hout-van Vroonhoven MCGN; Brouwer RWW; Oole E; Hamberg P; Haberkorn BCM; Helgason HH; de Wit R; Sleijfer S; Mathijssen RHJ; Martens JWM; Jansen MPHM; van Riet J; Lolkema MP
Eur J Cancer; 2022 Dec; 177():33-44. PubMed ID: 36323051
[TBL] [Abstract][Full Text] [Related]
37. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
38. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
40. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Armstrong AJ; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Berry WR; Zhang T; Harrison MR; Lu C; Chen Y; Galletti G; Schonhoft JD; Scher HI; Wenstrup R; Tagawa ST; Antonarakis ES; George DJ; Halabi S
JCO Precis Oncol; 2020; 4():. PubMed ID: 33154984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
